Among the cancers that claim young lives, neuroblastoma stands as one of the most relentless — taking roughly one in nine children lost to cancer, with fewer than half of high-risk patients surviving five years. A study published in Nature now offers a quiet but significant shift in how researchers understand the disease: RAS signaling, long considered a minor player in neuroblastoma because it rarely mutates there, appears to drive tumor growth even in its normal, unmutated form. If that insight holds in clinical trials, a class of drugs already in development could become relevant not for a
RAS inhibition shows promise against neuroblastoma regardless of mutation status
Neuroblastoma is an aggressive pediatric malignancy with 40-50% five-year survival rates in high-risk cases and accounts for 11% of all pediatric cancer deaths.
Even tumors without RAS mutations depend on normal RAS signaling to thrive
Mark
Why does it matter that RAS mutations are so rare in neuroblastoma if the protein still seems to drive the disease?
Mimi
Because most cancer drugs are designed to hit mutant versions of proteins—they're like locks built for a specific broken key. If you're only targeting mutant RAS, you miss the majority of tumors that rely on normal RAS. This work says the normal version is just as important to block.
Mark
So you're saying the cancer doesn't need the mutation to need RAS?
Mimi
Exactly. The tumor has learned to depend on RAS signaling even when the gene itself is intact. It's like the cancer is addicted to the signal, not the mutation.
Mark
What does that mean for a child diagnosed with neuroblastoma?
Mimi
Right now, treatment depends heavily on whether the tumor has certain mutations like MYCN. If this translates to the clinic, it could mean a single drug might work for many more patients, regardless of their specific genetic profile.
Mark
Is there a risk that blocking RAS everywhere could harm healthy cells?
Mimi
That's the real question for clinical trials. RAS is essential for normal cell function. The hope is that cancer cells are more dependent on it than healthy tissue, but that's something you only learn by testing in patients.
Mark
How close are we to that happening?
Mimi
The science is solid enough that trials should follow. But neuroblastoma is rare, so recruiting patients and funding trials takes time. The window between "this works in the lab" and "this helps children" is usually years.
Le Pouls
- Neuroblastoma kills children at a rate disproportionate to its rarity — 11% of all pediatric cancer deaths — and existing treatments leave high-risk patients with survival odds below 50%.
- The assumption that RAS inhibitors would only help the fewer than 2% of neuroblastoma patients with RAS mutations had quietly narrowed the field of therapeutic possibility.
- New laboratory and animal data show that RAS inhibition slows tumor cell growth, colony formation, and migration across multiple neuroblastoma subtypes — with or without RAS mutations present.
- Even wild-type, unmutated RAS appears to be an active accomplice in tumor progression, meaning the cancer may be exploiting normal cellular machinery rather than broken genes alone.
- The path forward points toward clinical trials that could test whether these laboratory findings translate into real survival gains for children — potentially expanding treatment options across the full neuroblastoma population.
Among the cancers that claim young lives, neuroblastoma stands as one of the most relentless — taking roughly one in nine children lost to cancer, with fewer than half of high-risk patients surviving five years. A study published in Nature now offers a quiet but significant shift in how researchers understand the disease: RAS signaling, long considered a minor player in neuroblastoma because it rarely mutates there, appears to drive tumor growth even in its normal, unmutated form. If that insight holds in clinical trials, a class of drugs already in development could become relevant not for a sliver of patients, but for nearly all of them.
Neuroblastoma is a cancer that moves fast and kills young. It arises in the sympathetic nervous system, accounts for roughly one in nine pediatric cancer deaths, and leaves fewer than half of high-risk patients alive five years after diagnosis. Researchers have long mapped its genetic drivers — MYCN amplification appears in about a quarter of cases — but a new study in Nature proposes a therapeutic strategy that may work regardless of which mutations a tumor carries.
The study focuses on RAS, a family of proto-oncogenes that mutate in fewer than two percent of primary neuroblastoma cases. Despite that rarity, evidence had been building that elevated RAS activity — even without mutation — might be fueling tumor growth. To test this, researchers deployed three distinct approaches to RAS inhibition: mutation-specific inhibitors, anti-RAS biologics, and a pan-RAS inhibitor capable of broadly blocking the protein.
Across laboratory cell lines representing different neuroblastoma subtypes — some with MYCN amplification, some without, some carrying RAS mutations, some not — the results were consistent. RAS inhibition slowed cell proliferation, reduced colony formation, and curtailed migration. The effect did not depend on mutation status.
Animal studies reinforced the finding. When wild-type RAS activity was suppressed in neuroblastoma lines implanted in mice, tumor growth slowed — suggesting that even genetically typical RAS signaling is something these tumors rely on to thrive.
The broader implication is what makes this work notable. Neuroblastoma is rare enough that designing treatments for narrow genetic subgroups is both scientifically and economically difficult. A strategy effective across mutation types — whether a tumor carries MYCN amplification, ALK deregulation, or no known driver mutation — could reach a far larger share of patients. Clinical trials would be the next step in determining whether these results survive contact with the full complexity of a child's disease.
Neuroblastoma kills children. It accounts for one in every nine pediatric cancer deaths, and for those diagnosed with high-risk disease, the five-year survival rate sits at roughly four in ten. The cancer arises in the sympathetic nervous system and moves fast. Researchers have long understood that certain genetic mutations drive the disease—MYCN amplification, for instance, appears in about a quarter of cases—but a new study published in Nature suggests that a different therapeutic angle may work regardless of which mutations a tumor carries.
The research centers on RAS, a family of proto-oncogenes that rarely mutate in primary neuroblastoma tumors. Less than two percent of cases show RAS mutations. Yet evidence has accumulated suggesting that elevated RAS activity, even without mutation, may fuel tumor growth and spread. A team of researchers set out to test whether blocking RAS signaling could slow neuroblastoma progression across different genetic backgrounds.
They used three approaches: mutation-specific inhibitors targeting KRAS, anti-RAS biologics, and a pan-RAS inhibitor that blocks the protein broadly. In laboratory cell lines representing different neuroblastoma subtypes—some with MYCN amplification, some without, some with RAS mutations, some without—the results were consistent. Direct RAS inhibition reduced how fast cells multiplied, cut down on colony formation, and slowed cell migration. The effect held across the board, regardless of mutation status.
Then they moved to living animals. When researchers suppressed wild-type RAS activity in certain neuroblastoma lines implanted in mice, tumor growth slowed. This matters because it suggests that even tumors without RAS mutations depend on normal RAS signaling to thrive. The implication is straightforward: blocking RAS might work as a treatment strategy for a much broader population of neuroblastoma patients than the tiny fraction carrying RAS mutations.
The work involved researchers across multiple institutions, supported by grants from the National Cancer Institute, the National Institute of General Medical Sciences, and the Department of Veterans Affairs. Some of the team hold patents related to RAS-targeting monobodies and have financial interests in biotechnology companies developing RAS inhibitors, a detail the authors disclosed transparently.
What makes this finding potentially significant is its breadth. Neuroblastoma is rare enough that developing treatments for narrow genetic subtypes can be economically difficult. A therapeutic approach that works across mutation types—whether a tumor has MYCN amplification, ALK deregulation, or none of the known driver mutations—opens a wider door. The next logical step would be clinical trials testing RAS inhibitors in neuroblastoma patients, to see whether the laboratory and animal results translate to actual survival benefit in children.
Citations marquantes
Targeted RAS inhibition, even in the absence of RAS mutation, may represent a promising therapeutic approach for neuroblastoma patients— Research findings from Nature study
Envie de l'histoire complète ?
Lire l'original sur Nature ↗
Health & Medicine